California Personal Injury Blog

On the heels of a recall of one lot of their skin care product, pharmaceutical manufacturer Ranbaxy Pharmaceuticals, Inc. has also announced that they are voluntarily recalling two lots of the antibiotic drug from the U.S. market. Drug maker Ranbaxy recently recalled one lot of their 40 milligram Sotret Isotretinoin capsules, a drug that can help acne sufferers have cleaner skin. The company’s second recall involves Lots No 1910779 and 1910782, both with an expiration date of May 2010.

The antibiotic is designed to be mixed with water to form a lotion that can be applied directly to the skin. The company issued the recall after some users complained that when the product was mixed with water, it changed color in ways that previous batches had not. It is unknown if anyone has been injured or disfigured by Sotret Isotretinoin, but anyone with unused product is encouraged to stop using the skin treatment immediately and contact the manufacturer. The FDA is investigating the company for failing to comply with recommended manufacturing practices at two of its plants.

Most pharmaceutical recalls involve drugs that have caused very serious health complications and even death. California pharmaceutical litigation lawyer Samer Habbas knows very well that companies that manufacture products of any kind have a responsibility to ensure that their products are safe to use. As an experienced Los Angeles pharmaceutical litigation lawyer, he has been helping victims and their families recover damages from the manufacturers of defective and dangerous drugs for many years. If you or someone you care for has been injured or lost due to prescription medication, call 888.848.5084 today to speak with Southern California pharmaceutical litigation attorney Samer Habbas and receive answers to your questions.

Resource link: Ranbaxy Announces Recall of Antibiotic in U.S.

Drug maker Hospira, Inc. has issued a recall for two of its drugs for the second time in six months due to manufacturing defects. The U.S. Food and Drug Administration recently issued a warning about the defects, prompting the manufacturer to recall Propofol and Liposyn. Propofol, an anesthetic, and Liposyn, an intravenous nutritional product, were recalled April 1. Hospira told the FDA that these two pharmaceuticals had been contaminated with particulates during manufacturing.

The Lake Forest, Illinois based drug maker had previously recalled Propofol and Liposyn in October 2009 due to an equipment failure at one of their plants. The FDA inspected the Clayton, North Carolina manufacturing facility in January and February of this year. The FDA also reviewed the company’s plant in Rocky Mount, North Carolina in January and found a failure to validate processes used for manufacturing undisclosed products.

“We have been working closely with the FDA to find solutions to these problems,” said a Hospira spokesperson who said that the company is conducting “a comprehensive review of its manufacturing operations to ensure compliance with applicable regulations.”

California pharmaceutical litigation lawyer Samer Habbas places an emphasis on client education. To that end, he would like to remind his readers that the manufacturers of any product have a legal obligation to ensure that their products are safe to use. If someone is injured or killed using the product, the manufacturer may be liable for damages. If you or someone you love has been harmed by a defective drug, Southern California pharmaceutical litigation attorney Samer Habbas may be able to help. Mr. Habbas has the experience and resources to handle cases against large pharmaceutical companies and offers free consultations to discuss your case. To schedule your free consultation, call his law offices today at 888.848.5084.

Resource link: Hospira Issues Second Drug Recall in 6 Months on FDA Warning